Zacks: Analysts Await Alexion Pharmaceuticals, Inc. (ALXN) to Announce $2.20 Revenue Per Share

Zacks: Analysts Await Alexion Pharmaceuticals, Inc. (ALXN) to Announce $2.20 Revenue Per Share

Wall Street brokerages expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will post $2.20 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Alexion Pharmaceuticals’ earnings. The lowest EPS estimate is $2.01 and the highest is $2.30. Alexion Pharmaceuticals reported earnings of $1.68 per share in the same quarter last year, which would suggest a positive year over year growth rate of 31%. The firm is expected to report its next earnings report on Thursday, April 25th.

On average, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $9.12 per share for the current year, with EPS estimates ranging from $7.86 to $10.03. For the next financial year, analysts forecast that the business will post earnings of $10.20 per share, with EPS estimates ranging from $8.78 to $12.19. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.54. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the company earned $1.48 earnings per share. The firm’s revenue was up 24.1% compared to the same quarter last year.

A number of equities analysts recently weighed in on ALXN shares. Credit Suisse Group restated a “buy” rating and set a $156.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, January 22nd. Raymond James restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Sunday, December 30th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 31st. Oppenheimer set a $165.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 14th. Finally, Citigroup lowered their target price on shares of Alexion Pharmaceuticals from $195.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, October 25th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $162.94.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 3,244 shares of the company’s stock in a transaction on Monday, December 31st. The shares were sold at an average price of $95.85, for a total value of $310,937.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total transaction of $307,728.65. Following the completion of the transaction, the executive vice president now owns 29,304 shares in the company, valued at $3,461,681.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,093 shares of company stock worth $929,603. Corporate insiders own 4.35% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ALXN. Jennison Associates LLC increased its holdings in shares of Alexion Pharmaceuticals by 43.1% in the third quarter. Jennison Associates LLC now owns 8,627,536 shares of the biopharmaceutical company’s stock valued at $1,199,314,000 after purchasing an additional 2,599,414 shares during the last quarter. FMR LLC increased its holdings in shares of Alexion Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock valued at $2,932,693,000 after purchasing an additional 1,581,376 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Alexion Pharmaceuticals by 164.2% in the third quarter. American Century Companies Inc. now owns 1,904,296 shares of the biopharmaceutical company’s stock valued at $264,716,000 after purchasing an additional 1,183,476 shares during the last quarter. Iridian Asset Management LLC CT increased its holdings in shares of Alexion Pharmaceuticals by 58.1% in the third quarter. Iridian Asset Management LLC CT now owns 2,365,078 shares of the biopharmaceutical company’s stock valued at $328,769,000 after purchasing an additional 868,886 shares during the last quarter. Finally, Clearbridge Investments LLC increased its holdings in shares of Alexion Pharmaceuticals by 15.4% in the third quarter. Clearbridge Investments LLC now owns 5,178,157 shares of the biopharmaceutical company’s stock valued at $719,816,000 after purchasing an additional 691,390 shares during the last quarter. Hedge funds and other institutional investors own 94.20% of the company’s stock.

Shares of NASDAQ ALXN traded up $2.15 during midday trading on Friday, reaching $122.20. The company’s stock had a trading volume of 10,466 shares, compared to its average volume of 1,935,029. The company has a quick ratio of 2.48, a current ratio of 2.88 and a debt-to-equity ratio of 0.31. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $140.77. The company has a market capitalization of $26.85 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 0.89 and a beta of 1.56.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: Why do earnings reports matter?

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment